PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617 - PubMed
6 hours ago
- #PSMA PET/CT
- #Prostate Cancer
- #Predictive Modeling
- PSMA PET/CT-derived total tumor volume (TTV) improves prediction models for outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 177Lu-PSMA-617.
- External validation of previous models using baseline variables showed C indexes of 0.70 for overall survival (OS), 0.68 for PSA progression-free survival (PSA-PFS), and 0.72 for PSA50 response.
- Replacing the dichotomized number of metastases with TTV increased the C index for OS by 0.04 and was independently associated with shorter OS, shorter PSA-PFS, and lower PSA50 odds.
- Higher TTV correlated with worse outcomes: hazard ratio of 1.35 for OS, 1.25 for PSA-PFS, and an odds ratio of 0.70 for PSA50, demonstrating better discriminatory ability than metastasis count.